Japan: Major Changes Due

29 September 1996

by Michael McLellan, IMS Japan KK

The reform of the health care system in Japan will be, without a doubt, the driving force behind the significant changes that will take place over the next several years.

The changes now being proposed by the Ministry of Health and Welfare are unprecedented in the Japanese National Health Insurance system's 35-year history. They include raising patient copayments from 10% for employed people to up to 50%, direct patient reimbursement for medical costs after treatment, generic listing (pricing) of original-brand drugs that have been on the NHI tariff for over 10 years, and reference pricing.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight